Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
Dynatronics is a leading medical device company committed to providing high-qualit...
Dynatronics is a leading medical device company...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in ...
CNS Pharmaceuticals is a pre-clinical stage bio...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Join the National Investor Network and get the latest information with your interests in mind.